Physician profile
Manver Razick
NPI 1073561304
$453.05
in general payments reported to CMS, 2019-2025
10 companies · $34.31 in 2025
The $34.31 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $68.94 · 2021: $18.33 · 2024: $153 · 2025: $34.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $187.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $153.17 | 2024 | |
| Abbvie INC. | $78.69 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.46 | 2019 | |
| Braintree Laboratories, INC. | $44.99 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.19 | 2019-2020 | |
| Pfizer INC. | $21.29 | 2019 | |
| Olympus America INC. | $17.36 | 2025 | Endoclot Phs |
| Medtronic, INC. | $16.95 | 2025 | Pillcam |
| Daiichi Sankyo INC. | $13.13 | 2019 | |
| Endo Pharmaceuticals INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manver Razick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.